Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 01/09/2018 - 12/31/2019

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

This self-study course is designed to assist the learner in developing and maintaining contemporary knowledge and skills in the pharmacotherapy management of sleep disorders. Content includes a comprehensive outline focused on etiology, risk factors, pathophysiology and treatment of sleep disorders. Specific focus is placed on identifying common signs and symptoms based on DSM-5 criteria, resolving drug therapy problems and developing an appropriate monitoring plan.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and is available to participants through the course expiration date. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Megan Maroney, PharmD, BCPP

Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ

No Relevant Financial Relationships to Disclose

External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Janssen Connect (division of Janssen Pharmaceuticals); Speakers Bureau: Otsuka-Lundbeck EXCEL Speaker's Bureau
Presentation will include discussion of off-label, experimental, and/or investigational use of drugs or devices: antihistamines, trazodone, mirtazapine, amitriptyline, gabapentin, tiagabine, quetiapine, olanzapine, melatonin, tryptophan, german chamomile, kava kava and valerian for insomnia, antidepressants and stimulants for narcolepsy and obstructive sleep apnea, methylxanthenes, estrogen, nasal decongestants, mirtazapine, paroxetine, xylometazoline, pantoprazole, zolpidem, eszopiclone and acetazolamide for obstructive sleep apnea, melatonin and vitamin B12 for circadian rhythm disorders, carbidopa/levodopa, cabergoline, pregabalin, iron, clonazepam, gabapentin, carbamazepine, clonidine, lisuride, amantadine, valproic acid, oxcarbazepine, rifaximin, botulinum neurotoxin, bupropion, selenium, transcranial magnetic stimulation, near-infrared spectroscopy, valerian, vitamin C and E and opioids for restless legs syndrome

Learning Objectives

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for sleep-wake disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of sleep-wake disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of sleep-wake disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in sleep-wake disorders. 
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for sleep-wake disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of sleep-wake disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with sleep-wake disorders.

Continuing Education Credit and Disclosures

Activity Dates: 01/09/2018 - 12/31/2019
ACPE Contact Hours: 1.5
ACPE Number: 0284-0000-18-012-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.5 contact hours of knowledge-based continuing education credit from CPNP approved programming.